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Abstract
Augmentation of the peak bone mass (PBM) may be one of the most effective interventions to reduce the risk of developing
osteoporosis later in life; however treatments to augment PBM are currently limited. Our study evaluated whether a greater
PBM could be achieved either in the progesterone nuclear receptor knockout mice (PRKO) or by using a nuclear
progesterone receptor (nPR) antagonist, RU486 in mice. Compared to their wild type (WT) littermates the female PRKO mice
developed significantly higher cancellous and cortical mass in the distal femurs, and this was associated with increased
bone formation. The high bone mass phenotype was partially reproduced by administering RU486 in female WT mice from
1–3 months of age. Our results suggest that the inhibition of the nPR during the rapid bone growth period (1–3 months)
increases osteogenesis, which results in acquisition of higher bone mass. Our findings suggest a crucial role for
progesterone signaling in bone acquisition and inhibition of the nPR as a novel approach to augment bone mass, which
may have the potential to reduce the burden of osteoporosis.
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Introduction
Osteoporosis is a major public health problem that currently
affects 44 million Americans. Approximately one of every two
women and one of every four men will suffer a fracture due to
osteoporosis during their lifetimes. Eighty percent of bone density is
genetically determined while the other 20% is determined by
lifestyle and environmental factors such as diet, exercise, smoking,
and various medications [1]. The two most significant risk factors
associated with the development of osteoporosis are the peak bone
mass achieved and the rate of bone loss. Peak bone mass is
dependent on the rate of bone growth, which is highest during
infancy and during the pubertal growth spurt. Adolescence is a
particularly critical period of bone acquisition, since the rate of bone
growth is nearly double that from earlier years, and approximately
40% of the peak bone mass is acquired from periosteal expansion.
At the end of puberty, the epiphyseal growth plates fuse and linear
bone growth ends. However, bone mass continues to increase both
at the endocortical and trabecular bone surfaces and within a few
years of the age of 20, 90–95% of the peak bone mass has developed
[2]. Although the intake of calcium and vitamin D through diet and
supplements and weight-bearing exercise during puberty have
modest impacts on the augmentation of peak bone mass [3,4,5,6],
interventions with greater efficacies have yet to be developed.
Progesterone is known for its effects on the reproductive system,
and its physiological roles in skeletal metabolism remains unclear.
In clinical studies, oral contraceptives that contained progesterone
[7,8] resulted in a modest reduction of bone mineral density
(BMD) that was within one standard deviation of placebo-treated
controls in both the central and peripheral skeleton
[9,10,11,12,13,14,15]. In postmenopausal women, treatment with
a synthetic progestin (norethisterone) did not prevent bone loss
[16,17]. In contrast, treatment with cyclic medroxyprogesterone
increased spinal cancellous bone density by approximately 1.7%
during a one-year long, randomized, double-blind, placebo-
controlled trial in premenopausal women with disturbed menstru-
ation [18]. In animal models, reports of progesterone’s effects on
bone density have been variable and are influenced by estrogen,
the dose of progesterone administered, skeletal site analyzed, and
the stage of skeletal maturation [19,20].
Progesterone nuclear receptors (nPR) are present in human
osteoblasts [21,22,23] and osteoclasts [24]. A high cancellous bone
mass phenotype was reported in female progesterone receptor
knockout mice (PRKO) in the proximal tibia metaphysis at 26 weeks
of age [25]. The investigators reported that a higher bone mass was
associated with higher surface-based bone formation rates that were
assessed in 24-week-old PRKO mice compared to control animals.
Interestingly, the nPR antagonist, RU486, administered at a
dose of 10 mg/kg for four weeks prevented bone loss in three-
month-old estrogen-deficient rats [26]. However, another study
reported that RU486 did not stimulate bone formation when used
at the same dose in normal, estrogen-intact, sexually mature three-
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month-old rats [27]. Based on these data, we hypothesized that the
‘‘timing’’ of the progesterone receptor’ inhibition is critical for
augmenting bone mass. We found that compared to the WT
littermates, female mice lacking nPR (PRKO) had accelerated
bone formation and cancellous bone gain in the distal femoral
metaphysis between 1–3 months of age, and the cancellous bone
mass was maintained thereafter. In contrast, the male PRKO mice
and WT littermates had similar bone acquisition from one to six
months of age, but the PRKO male mice had less bone resorption
and less age-related bone loss compared to WT littermates from 6–
12 months of age. RU486, administered immediately after
weaning in one to three-month old female WT mice recapitulated
the rapid gain in femoral bone mass and the high bone mass
phenotype. Our findings illustrate that the nPR inhibit bone
acquisition and bone formation in female mice; and that the
temporary inhibition of nPR during the linear bone growth period
may provide a novel approach to augment peak bone mass.
Results
Bones from female and male PRKO mice and WT littermates
(C57/BL6 backgrounds) were analyzed from 4–48 weeks (1–12
months) of age. The first evaluation was performed at four weeks
of age (one month) which is pre-pubertal time point that is just
prior to rapid skeletal acquisition. The second evaluation was
performed at 12 weeks of age (three months), which is a post-
pubertal time point when the peak bone mass has been mostly
achieved, bone mass acquisition has slowed, and the mouse
reproductive system is fully developed. The evaluation was
repeated every three months until the mice were 12 months old
to record longitudinal and cortical bone growth. We also
performed cell culture experiments using 12-week-old, mice when
the maximum bone growth was observed.
Body Weights
Body weights were recorded each month. The body weight
increased with age from 15 grams to 26 grams from four to 24
weeks of age. There were no differences in body weight between
the genotypes.
Gonadal hormones or reproductive hormones
Gonadal hormone levels have been reported to be similar
between PRKO and WT mice and our results agree with the
previous findings [28,29,30,31,32]. The gonadal or reproductive
hormone levels, from reproductively mature WT and PRKO mice
were similar at three months of age (estrogen in the females: WT
52613 pg/mL vs. PRKO 61615 pg/mL; progesterone in the
female: WT 7.263.1 ng/mL vs. PRKO 11.962.9 ng/mL;
testosterone in the males: WT 5.661.0 ng/mL vs. PRKO
6.261.8 ng/mL). Follicle-stimulating hormone (FSH) levels were
similar in the female but lower in the male PRKO mice (in
females: WT 4.4 62.3 pg/mL, PRKO 3.961.6 pg/mL; in males:
WT 27.765.3 pg/mL, PRKO 6.762.7 pg/mL). Inhibin A levels
were higher in the female PRKO and were similar in the male
mice (in females: WT 58.4614.3 pg/mL, PRKO 169.1638.9 pg/
mL; in males: WT 50.466.9 pg/mL, PRKO 41.367.2 pg/mL).
Mice without the nuclear PR had higher bone mass than
WT mice
In order to evaluate if the nPR was present in bone cells, we first
examined nPR expression using western blotting on both
osteoblasts and osteoclasts that were cultured from bone marrow
cells. Uteri from WT or PRKO mice were used as positive or
negative controls for nPR expression. We confirmed that the nPR
was expressed by both osteoblasts and osteoclasts in the WT mice
and that nPR expression was absent in the PRKO mice (Figure 1).
We then studied the effects of the nPR on bone acquisition in
experiments in which female and male PRKO mice or female WT
mice were treated with a PR antagonist.
The WT female mice had the highest cancellous bone mass in
the distal femur between 1–3 months of age. Cancellous bone
volume was lost at an average rate of 1.4% per month from 4–12
months of age. In contrast, the highest cancellous bone mass (bone
volume/tissue volume ratio, BV/TV) in the distal femur was
observed at three months of age, and the mass was approximately
70% higher in the PRKO female mice than the WT mice.
Cancellous bone volume loss was observed at an average rate of
0.4% per month from 4–12 months of age. At 12 months of age,
the female PRKO mice had 600% more cancellous bone than the
WT mice (Figure 2, n= 6–8 per genotype).
In the male mice, the highest cancellous bone mass was
observed in three-month-old WT mice, and bone mass was lost at
an average rate of 1.1% per month between 4–12 months of age.
In male, the highest femoral cancellous bone mass was observed in
six-month old PRKO mice, and this cancellous bone mass was
approximately 23% higher than that of the WT mice. In the
PRKO male mice, cancellous bone volume loss occurred at an
average rate of 0.9% per month between 3–12 months of age. The
cancellous bone mass in the distal femoral metaphyses was
approximately 33% higher in the male PRKO than in the WT at
12 months of age (Figure 2).
Cortical bone thickness measured at the mid-femoral shaft
increased with age for both sexes and was significantly higher in
the female PRKO mice than the WT mice from 3–12 months of
age. There was an age-related 70% increase in cortical bone
thickness in the males between 3–9 months of age, but no
difference was observed between the PRKO and the WT mice.
The femoral length increased from approximately 13 mm to
nearly 17 mm for both WT and PRKO in both male and female
mice from one to12 months of age. However, there were no
significant changes in the femoral length measurements between
the genotype and sexes at any of the time points (Figure 2).
PR inhibition during linear growth period induced higher
bone formation
To examine the in vivo cellular activities in the PRKO female
and male mice, we performed surface-based static and dynamic
histomorphometry on three-month-old mice. We observed that
both the surface-based bone formation parameters (mineralized
surface, MS/BS and bone formation rate/bone surface, BFR/BS)
and bone formation markers (propetide of type 1 procollagen
(P1NP), and osteocalcin) were 50% higher in both the female and
male PRKO mice than the WT mice (Figures 3, n= 8–10 per
genotype) at three months of age.
To assess osteogenesis, we cultured osteoblasts derived from
three-month-old WT or PRKO mice (n = 4–6 per genotype).
Alkaline phosphatase (ALP) levels and mineralized nodule
formation (stained by alizarin red, AR) were approximately
50%–100% higher in both the female and male PRKO mice
compared to the WT-derived cultures (Figure 4). RNA was
extracted from the osteoblast cultures and tested for expression of
genes associated with osteoblast maturation, Runx2, osterix,
osteocalcin and osteopontin (OPN). The levels of expression of
these genes were four to 13-fold higher in the cultures from the
female PRKO than the WT controls (Figure 5). Gene expression
of receptor activator of NK kappa B ligand (RANKL), an
osteoclast activator, was decreased by more than 4.5-fold in both
female and male PRKO mice compared to the WT control mice.
Progesterone in Bone
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The expressions of genes associated with apoptosis (Foxo1 and
FasL) were 15,30-fold lower in both the female and male PRKO
mice than the WT mice (Figure 5).
We also performed real time RT-PCR gene arrays to measure
osteogenesis and apoptosis from RNA extracted from the tibial
cortical bone from three-month-old WT and PRKO mice (n = 3
per genotype). The female PRKO mice had significantly higher
expression of osteogenesis-related genes (Figure 6A), while both
female and male PRKO mice had decreased expression of
apoptosis-related genes (Figure 6B).
PRKO mice and nPR inhibition reduced osteoclast
maturation and bone resorption
Next, we studied the activity of primary osteoclast cells that were
extracted from the long bones of the three-month-old mice (n= 3–5
for each genotype). We observed that mature osteoclasts, measured
by TRAP+ cells, were 200% lower in male PRKO mice (Figure 7B
and 7C). There was no difference between the number of TRAP+
cells in female PRKO mice (Figure 7A and 7C). In vivo bone
resorption, measured by urinary excretion of DPD/Cr and dynamic
histomorphometric measurement of the osteoclast surface, indicated
that bone resorption was decreased in PRKO mice, when
compared to the WT mice of the same sex (Figure 7D and 7E).
PR inhibition by RU486 during linear growth period
increased bone mass
To determine if we could reproduce the PRKO high bone mass
phenotype in female WT mice, we treated female WT mice with
RU486 from one to three months of age. Cancellous bone BV/TV
in the distal femur increased by 60% in female WT mice treated
with RU486 compared to the WT control mice, and the BV/TV
was similar to that of three-month-old PRKO mice (Figure 8). The
increase in bone mass was associated with increased bone formation
measured by serum bone formation markers, P1NP and surface-
based bone formation rate, BFR/BS. Total osteoclast surface was
not altered by RU486 treatment. However, the osteoclast
maturation (TRAP+ cells formation) and function (DPD/Cr) was
decreased following RU486 treatment (Figure 8).
Discussion
We found that nPR null mice develop a higher peak bone mass
when compared to the WT mice. At three months, the cancellous
peak bone mass was 70% higher and the femoral cortical bone
thickness was 30% greater in the female PRKO than in the WT
mice. Also, the nPR null female mice demonstrated a more
significant gain in bone mass during the linear bone growth period
(between one to three months of age) compared to the WT
controls. The male PRKO mice had 23% higher cancellous bone
mass when compared to the WT when the peak bone mass was
achieved at six-month of age. Both the female and male PRKO
mice had slower rates of bone loss than the WT controls with age.
Additionally, treatment with a progesterone antagonist, RU486,
during the rapid growth period (one to three months of age)
accelerated bone mass acquisition by stimulating of bone
formation in the female WT mice. These data suggest that
Figure 1. Expression of the progesterone nuclear receptor (PR-A and PR-B) in osteoblast and osteoclast. Bone marrow cells were
derived from WT mice and differentiated into osteoblasts in an osteogenic medium with ascorbic acid and b-glycerophosphate or into osteoclasts
with mCSF and RANKL stimulation. PR-A and PR-B were detected by immunofluoresence using PR (C19) primary antibody against both PR-A and PR-B
for mouse and FITC–Conjugated secondary antibody for osteoblasts (A, yellow arrow) or Texas-red conjugated secondary antibody for osteoclasts (B,
white arrows). DAPI was used to stain nucleus in the osteoclast culture (bright blue staining). C, osteoclast culture from the PRKO mice. Both PR-A and
PR-B were expressed by WT osteoblast (A, yellow arrow) and the WT osteoclast (B, white arrows) but not by the PRKO osteoclast (C). In osteoclasts,
the PR-A and PR-B expression was mainly observed around the nucleus, but weak expression was detected in the cytoplasm as well. Original
magnification, 1006. B, Western blot analysis of the expression of PR-A (molecular weight 96 kDa) and PR-B (molecular weight about 120 kDa)
proteins in osteoblasts and osteoclasts. Whole cell lysates were obtained from osteoblast or osteoclast cultures and probed with PR (C19) antibody.
Uterus tissue lysates from the WT were used as a positive control while the uterus tissue lysates from the PRKO were used as a negative control.
GAPDH was used as a housekeeping control. All the experiments were repeated three times.
doi:10.1371/journal.pone.0011410.g001
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progesterone influences bone acquisition and that inhibition of
nPRs during rapid bone growth can augment bone mass. Like
estrogen signaling, progesterone signaling seems to have inhibitory
effects on bone acquisition during the rapid bone growth period.
The pattern or bone growth and the age-related cancellous
bone loss of PRKO mice were similar to previous reports [33,34].
Rickard et al. reported female PRKO mice developed significantly
higher cancellous bone mass in the tibial metaphyses than the WT
Figure 2. Changes in the distal femoral cancellous bone volume in the WT and PRKOmice 1 to 12 months of age. MicroCT was initiated
when themice were one-month of age and repeated at three, six, nine and 12months on the same animals (n = 6–8 per genotype). The cancellous bone
volume from the distal femur (BV/TV), cortical thickness of the mid-femur and femur length were recorded. Data was presented as mean 6 SD.
doi:10.1371/journal.pone.0011410.g002
Progesterone in Bone
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mice at six and 26 weeks of age [25]. They observed that the
surface-based bone formation rate was higher in six-month-old
PRKO mice than the WT controls. The differences between our
results and those reported by Rickard et al may be they performed
their outcome measurements at different time points using
different animals, whereas we followed the same groups of mice
over a 12-month period. Additionally, Rickard et al. reported
cancellous and cortical bone changes in the humerus and the
tibiae, while we measured bone changes in the distal femurs and
mid-femur. Since the trabeculae and cortical bone architecture
and surface-based turnover differ between the tibia and the
humeral cortical bone, this may account for the differences
observed in the two studies. Despite the differences, our
histomorphometric results at the distal femur were similar to their
observations at the proximal tibae.
Progesterone can stimulate the proliferation and differentiation
of osteoblasts in human- and rat-derived osteoblast-like cells
[35,36,37,38,39,40,41]. In a murine osteoblast cell line culture,
progesterone inhibited osteoblast apoptosis [42]. We observed that
nPR (PR-A and PR-B) were present in both osteoblasts and
osteoclasts. As in other studies published on the PRKO mice, we
found estrogen and progesterone levels were similar between
PRKO and WT mice in females and the testosterone levels were
similar between the PRKO and WT mice in males [29,31,32].
Therefore, the PRKO bone phenotype may be due to a lack of
nPR signaling rather than the changes in systemic sex hormone
levels [30,31,32,43,44]. However, it is possible that the bone
phenotype was induced by progesterone’s non-genomic effects. To
further clarify whether the PRKO bone phenotype was derived
from the loss of genomic PR signaling, we treated female mice
with an nPR antagonist, RU486. Female mice were used for this
initial RU486 intervention study because the female PRKO mice
had a significantly greater increase in bone mass than in the males.
Inhibition of the nPR with RU486 in WT mice replicated the
bone turnover changes and increased bone mass similar to what
we observed in PRKO mice. In humans and rats [45,46,47],
RU486 administration was reported to lower serum progesterone
and increase serum estradiol, cortisol, testosterone and inhibin
Figure 3. Bone formation parameters measured in the three-month-old WT and PRKO mice. Markers for bone formation, P1NP (A) and
osteocalcin (B) that were measured from serum. Surfaced-based bone histomorphometry was performed at the distal femoral metaphysis that
included (C), mineralized surface (MS/BS), and (D), bone formation rate/bone surface (BFR/BS). Data was presented as mean 6 SD.
doi:10.1371/journal.pone.0011410.g003
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levels. These hormonal changes following RU486 administration
were similar to what we observed in the PRKO mice. The high
bone mass phenotype observed in the PRKO mice and in the WT
female mice treated with RU486 was associated with increased
bone formation in comparison to the WT control group.
Interestingly, we observed some sex-related differences in the
bone turnover and bone cell activities between three-month-old
PRKO and WT mice. In the female PRKO mice, there was
accelerated bone acquisition between one to three months of age
with increased osteoblastic differentiation, osteoblastic activity,
and activation of the osteogenesis pathway, in vivo mineral
apposition rate and bone formation rates. In contrast, the male
PRKO mice had a modestly bone mass phenotype that developed
later in their life when compared to their WT littermates. The
male PRKO mice showed decreased bone resorption measured by
gene expression, in vitro osteoclastogenesis, bone resorption marker
and bone histomorphometry at three months of age. The
decreased bone resorption in the male PRKO mice may be
associated with the decrease in the systemic FSH level. There is
some evidence that gonadotropin-releasing hormones are involved
in regulating bone mass. Deletion of the FSH receptor is associated
with an osteoporotic phenotype [48]. FSH directly stimulates
osteoclast formation by enhancing tumor necrosis factor (TNF)
production from immune cells [49]. Moreover, serum FSH
increases with female reproductive aging and prior to changes in
estradiol (E2) [50]. Inhibin is a gonadal hormone synthesized by
the ovary and testis that can inhibit FSH production by the
pituitary while activin can stimulate its release [51,52,53]. In
females, both inhibin A and B increase during puberty and the
levels correlate with the levels of estradiol and FSH in the ovary
and pituitary [54]. A decrease in negative feedback from inhibin A
and/or inhibin B may explain the increase in FSH with age
[50,55]. Inhibin A was recently reported to be an endocrine
stimulator of bone mass and strength [56]. The systemic changes
in gonadotropin-releasing hormone levels may account for the sex-
related and phenotypic differences we observed in the PRKO
mice.
We performed in vitro primary cell cultures to investigate nPR
signaling during osteoblastogenesis and osteoclastogenesis in the
absence of the systemic hormonal influence. In vitro osteoclast
maturation was lower in the male PRKO mice, which suggested
that nPR had intrinsic specific effects on these bone cells. Since we
Figure 4. In vitro osteogenesis accessed in three-month-old mice. Bone marrow cells were obtained from WT female or male mice and
cultured in osteogenic conditions for 14 days or 21 days and then stained for alkaline phosphatase (ALP, A and B, top pannels) or alizarin red (AR, A
and B, lower pannels). The ALP level was quantified by absorbance at OD 410 nm (C)and normalized by total cell protein. The AR level was quantified
by absorbance at OD 490 nm (D).
doi:10.1371/journal.pone.0011410.g004
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only measured hormonal changes and cellular activities at one
time point, it is possible that we missed the ‘‘peak’’ cellular actions
for the males. Further studies to evaluate time-dependent changes
in hormone levels and cellular activities, as well as age-related
changes of PR in the WT mice are necessary.
Another interesting observation was that pro-apoptotic gene
expression, such as the expression of Foxo1 and FasL, was
significantly lower in PRKO mice compared to WT mice. These
results were measured by using an apoptosis real time RT-PCR
gene array and confirmed by regular real time RT-PCR. The
Forkhead O (Foxo 1, Foxo 3a, Foxo 4) subfamily of transcriptional
factors are critical in cell fate decisions in response to growth
factors [57,58] and they serve as a defense mechanism against
oxidative stress [57,59,60]. Sex hormones like estrogen and
androgen have pro-apoptotic effects on osteoclasts but they also
have anti-apoptotic effects on osteoblasts and osteocytes [61].
Estrogen exerts protective effects against oxidative stress in many
tissues including the heart, brain, kidney and bone mainly through
an anti-apoptotic mechanism [62,63,64,65,66,67]. Only recently
has estrogen’s anti-apoptotic effect been linked to the inhibition of
the PI3K pathway via control of Foxo 1 transcription [68]. The
PR is reported to regulate the transcriptional activities of Foxos,
especially Foxo1, which controls endometrial decidualization
[69,70]. A reduction in the progesterone concentration within
the endometrium allows the cytoplasmic fraction of Foxo1 to enter
the nucleus and bind to its direct target genes, including Bcl2 and
FasL, and induce apoptosis [71,72]. Estrogen is proposed to act
through a paracrine mechanism by up-regulating FasL in
osteoblasts which leads to the apoptosis of the pre-osteoclasts
[73]. Testosterone and 5a-dihydrotesterone, reportedly inhibit
Foxo1 and Foxo3 transcriptional activity in an androgen receptor
(AR)-dependent manner [74,75]. Androgen/AR reduces Foxo1
DNA binding and represses Foxo 1-induced cell death [76]. Our
data suggests that androgens may regulate osteoblast survival via a
PR-dependent mechanism. In the absence of PR, a decrease in
Foxo1 and FasL transcription activities may prolong the osteoblast
lifespan. FOXO proteins exist in phosphorylated and unpho-
sphorylated forms and these alternative post-translational forms
have opposing actions on anti-oxidant detoxification, DNA
repair mechanisms and cellular apoptosis. Therefore, merely
monitoring the overall mRNA levels of Foxo1 does not definitively
assess its apoptosis capabilities. The hypothesis that PR regulates
cell survival through FOXO signaling warrants additional
investigation.
In addition to its classic nuclear receptor activity, some of
progesterone’s effects are ‘‘non-genomic’’ and can be explained by
extranuclear signaling that involves rapid activation of Src/MAPK
(mitogen-activated protein kinases), phosphoinositide 3-kinases/
Akt and JaK2/Stat3 signaling pathways without the transcrip-
tional activities of the receptors [77,78]. The PR B-isoform is more
important for activating the Src/MARK signaling pathway
outside the nucleus than the A isoform of the PR [77,79,80].
Non-genomic progesterone actions can be initiated at the cell
surface by progesterone membrane-bound receptors or through
the progesterone receptor membrane component 1 (PGRMC1)
[81,82]. Activation of the MAPK pathway is the key extra-nuclear
signaling pathway for steroid regulation of cell proliferation and
survival in various cell types including mesenchymal-derived cells
(osteoblasts and osteocytes) [83,84,85]. Progesterone acts directly
on osteoblasts through extra-nuclear signaling and activation of G-
protein coupled effectors such as phospholipase C, which leads to
increased intracellular calcium and inositol trisphosphate concen-
trations [86,87]. Postnatal activation of the G-proteins signaling
significantly enhances osteoblast function and increases cancellous
bone mass [88]. Our study with RU486 did not reproduce
completely the same bone phenotype as the PRKO mice, where
we observed RU486 treatment induced less bone gain compared
to the RPKO, suggesting the possible involvement of progesterone
Figure 5. Osteoblast differentiation and apoptosis-related gene expressions in osteoblastic cultures. Bone marrow cells were extracted
from 3-month-old mice and cultured with ascorbic acid and b-glycerophosphate from WT and PRKO mice to monitor osteoblastogenesis. RNA was
extracted from the cultures on day 14. Real-time PCR was performed to monitor gene expression for osteoblast differentiation (Runx2, Osterix,
Osteocalcin, OPG and RANKL) or apoptosis (Foxo1 and FasL). *p,0.05 compared with WT of the same sex.
doi:10.1371/journal.pone.0011410.g005
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extra-nuclear signaling in the regulation of bone cell activities.
Progesterone extra-nuclear signaling in osteogenesis and osteo-
clastogenesis is currently under investigation.
This study has a number of strengths including the use of a
unique PRKO mouse that lacks a nPR, and allowed the
assessment of skeletal acquisition to be assessed and thoroughly
characterized in the absence of this nuclear receptor. However,
there are some limitations of this study. For example there is not a
conditional or selective nPR knock out mouse, so we could not
control for the effects of deficient nPR signaling in other tissues.
Figure 6. Osteogenesis and apoptosis real time RT-PCR gene arrays. RNA was extracted from the tibiae after removal of the joint and bone
marrow cells from three-month-old WT and PRKO mice and run for osteogenesis real-time RT-PCR gene array (A) or real time RT-PCR apoptosis gene
array (B). All the genes present in this figure were significantly differ from the WT of the same sex (p,0.05).
doi:10.1371/journal.pone.0011410.g006
Progesterone in Bone
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Figure 7. Bone resorption parameters. A, Bone marrow cells were derived from three-months old female or male mice (n = 3–4/genotype) of all
genotypes and were treated in osteoclast medium that contained mCSF and RANKL for seven days. The cells were stained with TRAP to identify the
osteoclasts (A and B, black arrows show TRAP+ osteoclast. Original magnification 46). Cells with more than three nuclei were defined as TRAP+. C,
qualification of the TRAP+ cells. D, DPD/Cr, was measured from the urine. E, Osteoclast surface was measured from the trabecular surface of the distal
femoral metaphysis. N = 8-12/genotype for DPD/Cr and in vivo bone histomorphometry measurements.
doi:10.1371/journal.pone.0011410.g007
Figure 8. Bone mass and bone formation changes with RU486 treatment. One month-old female WT mice were treated with vehicle or
RU486 (500 mg/d, 5x/week for two months). MicroCT was performed at the distal femurs to measure the cancellous bone volume (A). Bone formation
was measured in either serum (P1NP, B) or at the distal femurs by surface-based bone histomorphometry (bone formation rate/bone surface, BFR/BS;
C). Bone resorption was measured in the urine (DPD/Cr, D), at the distal femurs by surface-based bone histomorphometry (osteoclast surface, Oc.S/
BS; E) and from bone marrow osteoclastic cultures (TRAP+, F). *p,0.05 compared with WT.
doi:10.1371/journal.pone.0011410.g008
Progesterone in Bone
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Other investigators have previously reported on the reproductive
and neurobiological aspects of the PRKO mice
[28,29,30,31,32,44,89,90]. We chose to use RU486 since it was
the only pharmacological compound that was commercially
available to block nPR. Because RU486 is not PR selective and
it is also a partial GR antagonist, this may have confounded our
observations. We are not advocating for the use of RU486 to
prevent or treat osteoporosis, as it also acts as an anti-cortisol drug,
which may induce an Addision-like disease with prolonged use.
Another concern involving RU486 is its potential detrimental side
effects, including the increased risk for endometrial cancer.
However, despite the toxicity of RU486, we evaluated if a very
short treatment regimen during skeletal modeling would augment
bone mass. Additional studies with more selective nPR inhibitors is
now warranted to further evaluate our preliminary findings.
In conclusion, mice that lack functional nPR acquire greater
bone mass than WT controls. The absence of nPR is associated
with increased bone formation in vivo and osteogenesis in vitro
compared to age-similar controls. The high bone mass phenotype
was more pronounced in the female PRKO mice than the males.
Selective inhibition of the nPR with RU486 in female mice,
partially reproduced the higher bone mass phenotype observed in
the PRKO female mice. These data suggest that selectively
inhibition of the nPR with a PR selective modular during skeletal
acquisition may be a potential approach for augmenting bone
mass. Further investigation of the roles of PR signaling in bone
remodeling is needed.
Materials and Methods
Generation of the mice and experimental protocol
The PRKO breeding pairs were obtained from a research
group from Dr. Judith Turgeon’s laboratory at University of
California, Davis. The heterozygous breeding pairs were used to
generate WT, heterozygous and homozygous mice for the study.
All animals were treated according to the United States
Department of Agriculture (USDA) animal care guidelines with
the approval of the UC Davis Committee on Animal Research.
Mice were weaned at three weeks of age and genotyped using the
following primers: P1, 59-TAG ACA GTG TCT TAG ACT CGT
TGT TG-39; P3, 59-GAT GGG CAC ATG GAT GAA ATC-39;
and N2, 59-GCA TGC TCC AGA CTG CCT TGG GAA A-39,
which were used for genotyping in previous studies [25,29,32,43].
MicroCT measurements
Repeated in vivo microCT scans were performed in groups of
mice (n = 6–8 per genotype) from all the genotypes between 1–12
months of age. The right distal femur and the mid-femur from
each animal was scanned and measured using the VivaCT 40
(Scanco Medical, Bassersdorf, Switzerland), with a voxel resolution
of 10 mm in all three spatial dimensions. We used a monoenergetic
(70 KeV) X-ray sources that was reported to be safe for both
structural bone endpoints and bone marrow cell viabilities in small
animals [91]. The lengh of the femur was measured from a two-
dimensional scout view image prior to each scan. We evaluated
200 slices, which were initiated approximately 0.2 mm away from
the distal end of the growth plate. The slides covered a total
metaphyses tissue volume of 2–3.5 mm3 for each scan and were
used to obtain the cancellous bone volume/total volume (BV/TV)
and cortical bone thickness at the mid-femoral region [92,93,94].
Anti-nPR treatment with RU486
A separate group of one-month-old female WT mice, (n = 6),
were treated with either RU486 (500 mg/mouse, subcutaneous
injection, 3x/week) or vehicle (sesame oil) for two months. Mice
were sacrificed at three months of age (two months post-
treatment). Repeated in vivo microCT scans were performed at
one month and three months using the same methods as above.
Biochemical measurements
We collected serum from all the mice that we used for cell
culture and bone histomorphometry to measure biochemical
markers of bone formation. Serum levels of procollagen I N-
terminal propeptide (P1NP) (Immunodiagnostic Systems Inc.,
Fountain Hills, AZ), osteocalcin (Biomedical Technology,
Stoughton, MA), urine deoxypyridinoline (DPD/Cr) (Quidel
Corporation, San Diego, CA) and gonadal and reproductive
hormones (P, E2, FSH and inhibin A, ALPCO Diagnostics) were
determined using the enzyme-linked immunosorbent assay
(ELISA). The manufacturer’s protocols were followed and all
samples were assayed in duplicate. A standard curve was
generated from each kit and the absolute concentrations were
extrapolated from the standard curve. The coefficients of
variations (CVs) for inter-assay and intra-assay measurements
were less than 10% for all assays and were similar to the
manufacturer’s references [92,93,94].
Bone histomorphometry
To obtain the surface based bone turnover measures, groups of
three-month-old mice from all the genotypes (n = 6–8/genotype)
or RU486 treated WT mice were sacrificed. These mice were
injected with 20 mg/kg alizarin red and 10 mg/kg calcein seven
and two days before sacrifice. The right distal femurs were
removed from each mouse and fixed in neutral phosphate-
buffered formaldehyde, dehydrated in graded concentration of
alcohol, embedded undecalcified in methyl methacrylate and
sectioned using a microtome (Leica/Jung 2255). Bone histomor-
phometry was performed using a semi-automatic image analysis
system (Bioquant Image Analysis Corporation, Nashville, TN)
linked to a microscope that was equipped with transmitted and
fluorescent light. The analyses were performed in the secondary
spongiosa of the distal femurs, which included the trabecular area
between 100 mm to 300 mm distal to the growth plate and
excluding the cortex. Bone turnover measurements included
single- (sL.Pm) and double-labeled perimeter (dL.Pm), interlabel
width (Ir.L.Wi), osteoclast number and perimeter. These indices
were used to calculate the mineralized surface (MS/BS), mineral
apposition rate (MAR), surface-based bone formation rate (BFR/
BS) and osteoclast surface (Oc.S/BS) [94,95,96].
Primary osteoblast culture and assays
The tibia and the left femur bone marrow cells were harvested
from the femurs of three-month old WT or PRKO mice from both
sexes. These bones and the serum from these mice were also used
for bone histomorphometry and bone biochemical marker
measurements. The cells were flushed out and plated at 36106
in 6-well plates in primary medium with phenol red free a-MEM,
10% fetal bovine serum (FBS) and 1% antibiotics. At day 5, the
cells were replenished with the secondary medium containing all
the ingredients of the primary medium plus 50 mg/ml ascorbic
acid and 10 mM b-glycerophosphate. The cell cultures were fixed
in 10% neutral buffered formalin on days 14 and 21, and each well
was assayed for alkaline phosphatase (ALP) activity and mineral-
ization (alizarin red staining). ALP activity was determined by
staining the cells with a solution consisting of equal parts of p-
nitrophenol phosphate (Sigma 104) and alkaline buffer solution
(Sigma 221) [97]. All procedures were repeated in quadruplicate.
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Osteoclast culture
Bone marrow cells were collected from three-month-old WT or
PRKO mice as described above. For the RU486 experiment,
three-month-old female WT mice (n = 3/group) were treated with
RU486 (500 mg/mouse, subcutaneous injection, 3x/week) for 1
week. Bone marrow cells were collected from the femurs. Cells
were cultured in 24-well plates at 16106/well with 10 ng/ml
macrophage colony-stimulating factor (M-CSF). After two days,
non-adherent osteoclast precursors were transferred to a new plate
and maintained in aMEM, 10% FBS, 101 ng/ml m-CSF, 50 ng/
ml RANKL. For the tartrate-resistant acid phosphatase (TRAP)
assay, the cells were stained for TRAP using the Sigma Acid
Phosphatase Leukocyte Kit according to the manufacture’s
instructions. Multinucleated (more than three nuclei per cell)
TRAP+ cells, identified by a dark purple red color, were
considered mature osteoclasts. All procedures were repeated in
quadruplicate.
Western Blots/Antibodies:
Protein lysates were obtained from osteoblast or osteoclast
culture in WT or PRKO mice in cold RIPA buffer. Debris was
removed by centrifugation and the protein concentration was
measured by the BioRad DC kit (Bio Rad). Immunoprecipitates
were analyzed by SDS-PAGE and western blot analyses using
standard conditions with the antibody against PR (PR C-19),
Santa Cruz Biotechnology). Immune complexes were visualized
following incubation with horseradish peroxidase–conjugated
secondary antibody. Protein bands were detected with chemilu-
minescence (ECL) detection system (Amersham Biosciences).
Quantification of the intensity of the bands in the autoradiograms
was performed using a Kodak imaging system and analyzed by
SCION IMAGE. Normalization was performed with the
glyceraldehydes 3-phosphate dehydrogenase (GAPDH) antibody.
RNA preparation and real-time RT-PCR
Total RNA was extracted from cell culture or from tibiae. After
removal of the joint and bone marrow, the total RNA from bone
was isolated using a modified two-step purification protocol
employing homogenization (PRO250 Homogenizer,
10 mm6105 mm generator, PRO Scientific IN, Oxford CT) in
Trizol (Invitrogen, Carlsbad, CA) followed by purification over a
Qiagen RNeas column (Qiagen, Valencia, CA). PCRs were run 3–
5 times for individual samples in each group. Real-time reverse-
transcript (RT) PCR was carried out on ABI Prism 7300 (Applied
Bioscience, Foster City, CA). Primer sets for real-time RT-PCRs
were purchased from SABioscience (Frederick, MD). All the test
genes were expressed relative to a control gene, b-actin or
GAPDH. The results were expressed as fold changes from WT
group, where fold changes = 22DDCt. Osteogenesis and apoptosis
real time RT-PCR gene arrays (n = 3 per genotype) were
purchased from SABioscience (Frederick, MD). There were 96
genes (wells) for each array including test genes, house keeping, no
primer and no cDNA controls (detailed gene information can be
found at http://www.sabiosciences.com/RTPCR.php). We ex-
cluded genes that had Ct values of 36 or more cycles as low
expression levels can result in large-fold changes, but the
differences were not significant. After these exclusions, 71 genes
remained on the osteogenesis RT-PCR arrays, and 70 genes were
left on the apoptotic PCR arrays. Gene expressions that were
significantly differed from WT were presented in this report.
Statistics
The means and standard deviations were calculated for all
parameters from all groups. Repeated measures analysis of
variance (ANOVA) was used to evaluate parameters derived from
repeated in-vivo micro-CT scans such as cancellous bone volume
(BV/TV), cortical thickness (Ct,Th) and femoral length and
Bonferroni post-tests were used to compare time (age)-dependent
changes within the same sex or between WT and PRKO at the
same time point. Peak bone mass was defined as the highest BV/
TV value obtained that was significantly different from baseline.
For the measurements collected in three-month-old mice (bone
markers, cell culture assays, bone histomorphometric parameters),
two-way ANOVA was used to invest the main effects of sex,
genotype and their interactions. Bonferroni post-hoc tests were
used to make comparisons between the groups (SPSS Version 12,
SPSS Inc., Chicago, IL; GraphPad Prism, La Jolla, CA). The real
time RT-PCR findings were expressed as fold changes from the
WT. Unpaired t-test was used to detected difference between
PRKO and WT mice within the same sex. Differences were
considered significant at p,0.05.
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